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Most people with diabetes develop severe complica-
tions of the autonomic nervous system; yet, the
underlying causes of many diabetic-induced dysau-
tonomias are poorly understood. Here we explore
the idea that these dysautonomias results, in part,
from a defect in synaptic transmission. To test this
idea, we investigated cultured sympathetic neurons
and show that hyperglycemia inactivates nAChRs
through a mechanism involving an elevation in reac-
tive oxygen species and an interaction with highly
conserved cysteine residues located near the intra-
cellular mouth of the nAChR channel. Consistent
with this, we show that diabetic mice have depressed
ganglionic transmission and reduced sympathetic
reflexes, whereas diabetic mice expressing mutant
postsynaptic nAChRs that lack the conserved cys-
teine residues on the a3 subunit have normal syn-
aptic transmission in sympathetic ganglia and
normal sympathetic reflexes. Our work suggests
a new model for diabetic-induced dysautonomias
and identifies ganglionic nAChRs as targets of hyper-
glycemia-induced downstream signals.
INTRODUCTION
The autonomic nervous system controls homeostasis through
several intricate neural circuits, including nuclei in the hypothal-
amus and brainstem, cholinergic preganglionic neurons in the
spinal cord, peripheral neurons in sympathetic and parasympa-
thetic ganglia, and peripheral feedback from hormones and
mechano-, chemo-, and thermosensory nerves. Diseases that
disturb the function of these circuits produce dysautonomia or
autonomic insufficiency (Low, 2002), a heterogeneous disorder
encompassing a wide range of abnormalities and unique syn-
dromes that adversely affect the quality of life and shorten life
expectancy (Freeman, 2005). Most people with diabetes developautonomic neuropathies or dysautonomias (Vinik et al., 2003;
Dyck et al., 1993). Symptoms range in severity and include
cardiac arrhythmias, orthostatic hypotension, gastrointestinal
abnormalities, andpoor control of thecirculation. Diabetic cardio-
vascular dysautonomia is among themost commonand troubling
because it causes abnormalities in heart rate and central and
peripheral vascular dynamics; as a result, people with diabetes
have an increased incidence of asymptomatic ischemia and
a predisposition to malignant arrhythmogenesis and sudden
cardiac death (Vinik and Ziegler, 2007; Duby et al., 2004).
Clinically, diabetic autonomic neuropathies or dysautonomias
usually become apparent in patients who have had diabetes
for several years, and the syndrome is generally thought of as
a progressive, late-stage complication of diabetes, although
the underlying mechanisms that lead to the progression of
this complication are poorly understood. A current hypothesis
is that diabetic autonomic neuropathy is a disease of sympa-
thetic nerve endings (Schmidt, 2002). Support for this comes
from observations that in the prevertebral superior mesenteric
and celiac ganglia of patients with diabetes many sympathetic
nerve endings are significantly enlarged and appear dystrophic
(Schmidt, 1996). On the other hand, there are no structural
abnormalities in the paravertebral ganglia that regulate the
cardiovascular system (Schmidt et al., 2008), suggesting that
diabetic cardiovascular dysautonomia results from a functional
rather than structural defect. Although seldom considered, one
cause for dysautonomias in diabetics could be a defect in
synaptic transmission in autonomic ganglia.
Synapses in autonomic ganglia are the last step in the chain
linking the integrative activity of the CNS to tissues and organs
in the periphery. Normally, synaptic transmission in autonomic
ganglia is strong and stable; however, if ganglionic synapses
malfunction due to some disease process, this vital link between
the CNS and the periphery becomes disrupted and dysautono-
mias ensue. A good example of such a disease is autoimmune
autonomic ganglionopathies (AAG), a rare autoimmune disease
that produces dysautonomias by disrupting the function of
ganglionic a3-containing nAChRs (Vernino et al., 2000, 2009;
Klein et al., 2003).
Here we show that hyperglycemia causes a defect in synaptic
transmission in sympathetic ganglia. We go on to show that thisNeuron 66, 827–834, June 24, 2010 ª2010 Elsevier Inc. 827
Figure 1. Hyperglycemia Depresses Fast Synaptic Transmission in
Sympathetic Ganglia
(A) Nerve-evoked excitatory postsynaptic potentials (EPSPs) recorded intra-
cellularly from sympathetic neurons from control mice at 1 week, 2 weeks,
1 month, and 3 months after injection with control buffer (upper row) or from
mice 1 week, 2 week, 1 month, and 3 months after becoming diabetic as
neonates (lower row). (B) Average integrated EPSP sizes recorded from
sympathetic neurons inmice 1week (n = 35 neurons), 2weeks (n = 27), 1month
(n = 25), and 3 months (n = 58) after becoming diabetic. The EPSPs were
normalized to the average integrated EPSP on control sympathetic neurons
from 3-month-old mice. All values are the means ± SEM expressed as
a percent of control. The solid lines are polynomial function. (C) Ratio of the
average integrated EPSP sizes recorded from sympathetic neurons in diabetic
mice to those in age-matched control mice at different times after the onset of
diabetes. The depression of synaptic transmission becomes progressively
more severe with time after onset. The solid line is a single exponential func-
tion. (D) Sympathetic drive to the heart measured as the difference between
heart rates with atropine alone and atropine together with propanolol, in
control mice (Control; n = 12 mice), diabetic mice (STZ; n = 15), mice treated
simultaneously with STZ and insulin (STZ + Insulin; n = 5), and a3 KO mice
(a3 KO; n = 10). Each bar is the mean bpm ± SEM. (E) Core body temperature
measured for up to 3.5 hr at 4C from a 3-month-old control mouse, a
3-month-old mouse made diabetic with STZ at 2 months, and a 2-month-old
a3 KO mouse. (F) Core body temperature from control mice (Control; n = 6
mice), a3 KO mice (a3 KO; n = 6), mice made diabetic with STZ (STZ; n = 6),
and mice treated simultaneously with STZ and insulin (STZ + Insulin; n = 3).
Each bar is the mean ± SEM. ***p < 0.001 in (B), (D), and (F).
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Hyperglycemia Inactivates Neuronal nAChRssynaptic defect results from hyperglycemia’s effect on postsyn-
aptic receptor function and that diabetic-induced dysautono-
mias can be reduced when the postsynaptic nAChRs are pro-
tected from these detrimental effects of hyperglycemia.
RESULTS
Hyperglycemia Depresses Synaptic Transmission
in Sympathetic Ganglia
To test whether hyperglycemia causes a synaptic defect in
sympathetic ganglia, we made neonatal and young adult mice
diabetic by injecting them with streptozotocin (STZ; 60 mg/kg
i.p.), a drug that destroys insulin-producing pancreatic beta cells
(Lenzen, 2008; Junod et al., 1969). Two to three days after STZ
injection, blood glucose concentrations in 26 of 30 of these
STZ-treated mice increased from 5–7 mM to 22–30 mM and
remained above 25 mM for at least an additional 3 months.
To measure synaptic transmission in sympathetic ganglia, we
stimulated the preganglionic nerve and used intracellular elec-
trodes to record excitatory postsynaptic potentials (EPSPs) on
postsynaptic sympathetic neurons in intact superior cervical
ganglia. In ganglia from control mice, a maximal stimulus to
the preganglionic nerve evoked large suprathreshold EPSPs
that increase in magnitude over time (Figures 1A and 1B). In
contrast, the nerve-evoked EPSPs were significantly depressed
on sympathetic neurons in ganglia from diabetic mice as early
as 1 week after the onset of diabetes (Figures 1A–1C), and the
depression became more severe over time (Figure 1C). The
depression in synaptic transmission was similar in mice injected
with STZ as neonates and in those injected with STZ as young
adults. To rule out some unanticipated action of STZ on synaptic
transmission, we exogenously supplied insulin through a
slow-release pellet (2 U/24 hr/pellet) to mice at the time of STZ
treatment; the nerve-evoked EPSPs (1216.36 mV*s ± 246.37,
n = 11) in the SCG of these mice were not significantly different
from those in ganglia of untreated, aged-matched control mice
(1136.855 ± 128.7004, n = 25; p > 0.2). These results show
that diabetes severely depresses synaptic transmission in
sympathetic ganglia.
Dysautonomias
Next, to determine whether the depression in synaptic transmis-
sion in sympathetic ganglia of diabetic mice correlates with
a reduction in sympathetic nerve activity, we investigated nonin-
vasively two end points of sympathetic nerve activity: tonic
sympathetic drive on heart rate and thermoregulation (Bachman
et al., 2002; Axelsson, 1971). In addition, we also investigated
these end points in a3 KO mice; SCG in a3 KO mice have no
synaptic transmission (Krishnaswamy and Cooper, 2009; Ras-
sadi et al., 2005; Xu et al., 1999), and therefore these mice
provide a measure of the maximum reduction in these sympa-
thetic reflexes when ganglionic transmission is completely
absent.
To measure the effects of tonic sympathetic nerve activity on
heart rate, first we treated mice with atropine (1 mg/kg i.p.) to
block muscarinic receptors, then we measured the difference
in heart rate before and after treating mice with propranolol
(1 mg/kg i.p.), a drug that blocks b-adrenergic receptors.828 Neuron 66, 827–834, June 24, 2010 ª2010 Elsevier Inc.The sympathetic drive to the heart in both 5-week-old diabetic
mice and a3-KO mice were considerably reduced compared to
that in aged-match control mice (Figure 1D).
As a second measure of sympathetic function, we examined
thermoregulation during cold exposure (Bachman et al., 2002).
Figure 2. Increasing Glucose to 25mMElevates ROS in Sympathetic
Neurons and Produces a Use-Dependent Rundown of ACh-Evoked
Currents
(A) DIC and fluorescent images of neurons cultured in 5 mM glucose for
2 weeks or in 5 mM glucose for a week followed by 25 mM glucose for a
week and loaded with CM-H2DCFDA for 1 hr. The bar graph shows the
average DCFDA fluorescence intensity in arbitrary units for neurons cultured
in 5 mM glucose for 2 weeks (n = 30 neurons) or in 5 mM glucose for a week
followed by 25 mM glucose for a week (n = 30). (B) Fluorescent images of
neurons cultured in 5 mM glucose for 2 weeks or in 5 mM glucose for
a week followed by 25 mM glucose for a week and immunostained for tyrosine
hydroxylase (TH, top) and protein adducts of 4-HNE (bottom). The graph
shows the average HNE fluorescence intensity in arbitrary units for neurons
cultured in 5 mM glucose for 2 weeks (n = 32 neurons) or in 5 mM glucose
for a week followed by 25 mM glucose for a week (n = 32). (C) Currents evoked
by a series of 1 s ACh (100 mM) applications delivered at 15 s intervals on
neonatal mouse SCG neurons cultured in 5 mM glucose for the first week
and then 1 week in 5 mM glucose (top), 1 week in 25 mM glucose (middle),
or 1 week in 25 mM glucose and perfused intracellularly with a-lipoic acid
and catalase (bottom). Every fourth trace is shown for clarity. (D) Ratio of the
30th ACh-evoked current to the first in the series (I30/I1) for neurons cultured
in 5 mM glucose for the first week and then 1 week in 5 mM glucose (n = 7
neurons), 1 week in 25 mM glucose (n = 14), 1 week in 25 mM glucose and
perfused intracellularly with a-lipoic acid and catalase (n = 21), 1 week in
25 mM glucose together with insulin (30 nM) (n = 8), 3 days in 25 mM glucose
together with aminoguanidine (AG, 250 mM) (n = 8). Each bar in (A), (B), and (D)
is the mean ± SEM; ***p < 0.001. The scale bar in (A) and (B) is 20 mm.
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Hyperglycemia Inactivates Neuronal nAChRsWhen 2-month-old control mice were placed at 4C, their core
body temperature remained constant for at least 2–3 hr.
In contrast, when aged-matched a3 KO mice or diabetic mice
were placed at 4C, their core temperature dropped by several
degrees within 2 hr (Figures 1E and 1F). Both the decrease in
heart rate and the lack of thermoregulation in diabetic mice
suggest that sympathetic nerve activity is low; although other
factors may also contribute to the lack of thermoregulation in
diabetic mice, these results are consistent with the depression
in synaptic transmission in sympathetic ganglia.
Depressed Synaptic Transmission in Leptin (ob/ob)
and Leptin Receptor (db/db) Mutant Mice
To test further the idea that synaptic transmission is depressed in
autonomic ganglia during diabetes, we investigated young adult
(10- to 14-week-old) ob/ob and db/db mice, models for type 2
diabetes; these mice develop diabetes and hyperinsulinemia
after the first postnatal month because of a disruption in leptin
signaling (Chen et al., 1996; Zhang et al., 1994; Coleman,
1978). Upon preganglionic nerve stimulation, the nerve-evoked
EPSPs on sympathetic neurons in the SCG were considerably
reduced in young adult diabetic ob/ob mice (45.17% ± 7.43%
of EPSP size in aged-matched heterozygote +/ob mice; n = 24)
and in adult diabetic db/db mice (51.41% ± 7.43% of EPSP
size in aged-matched heterozygote +/db mice; n = 25); at the
time of the experiment, all ob/ob and db/db homozygote mice
had blood glucose levels >25 mM. Taken together with the
results from STZ-treated diabetic mice, these data indicate
that synaptic transmission in sympathetic ganglia is depressed
in completely different diabetic models.
Hyperglycemia Inactivates Nicotinic Acetylcholine
Receptors on Autonomic Neurons
To understand how hyperglycemia depresses synaptic trans-
mission in diabetic mice, we investigated SCG neurons exposed
to hyperglycemic conditions in culture. When neurons are
exposed to hyperglycemic conditions, they increase their uptake
of glucose, and this additional glucose alters several signaling
pathways that could affect the function of sympathetic neurons
(Tomlinson and Gardiner, 2008), for example by elevating ROS.
To test whether hyperglycemia elevates ROS in SCG neurons,
we cultured neonatal SCG neurons in normal 5 mM glucose
initially and then elevated glucose to 25 mM at 1 wk to mimic
conditions in diabetes. Neonatal SCG neurons develop well in
both 5 mM and 25 mM extracellular glucose (Figure 2A); in
25 mM glucose, these neurons had clear, centrally located
nuclei, continued to extend long processes and grow in size,
and synthesized tyrosine hydroxylase. To quantify neuron via-
bility, we counted neurons in cultures before and after elevating
glucose. One week after elevating glucose, the number of neu-
rons was 97.5% ± 2.3% (mean ± SEM; n = 5 cultures) of the
number before elevating glucose, and not significantly different
(p > 0.2) from the number in sister cultures left in 5 mM glucose
throughout (>99.4% ± 0.01% [mean ± SEM; n = 5 cultures]).
To determine relative changes in ROS levels in neurons when
exposed to high glucose, we used the ROS indicator dye CM-
H2DCFDA, or in some cases, we immunostained neurons for
protein adducts of 4-hydroxy-2-nonenal (HNE), a major productof endogenous lipid peroxidation. Our results show that hyper-
glycemia caused both a mild elevation in ROS-induced fluores-
cence and an increase in HNE staining (Figures 2A and 2B).
In a previous study, we showed that elevations in cytosolic
ROS caused a use-dependent inactivation of nAChRs onNeuron 66, 827–834, June 24, 2010 ª2010 Elsevier Inc. 829
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Hyperglycemia Inactivates Neuronal nAChRssympathetic neurons (Campanucci et al., 2008). Given our
results in Figures 2A and 2B that hyperglycemia causes a mild
elevation in ROS, therefore we asked whether hyperglycemia
also causes a use-dependent inactivation of nAChRs. To test
this, we investigated nAChR function using whole-cell voltage
clamp. Repeatedly applying ACh (100 mM for 1 s) to neurons
maintained in 5 mM glucose (controls) at 15 s intervals for
5–10 min evoked large inward currents of constant amplitude
(Figure 2C); the peak current amplitude of the 30th application
(I30) was close to that of the first (I1) (Figure 2D). In contrast,
repeatedly applying ACh at 15 s intervals to neurons exposed
to 25 mM glucose caused a use-dependent rundown of the
ACh-evoked currents (Figure 2C); I30/I1 was less than 30%
(Figure 2D) and did not recover for as long as we could record
from the neuron (at least 1 hr).
Hyperglycemia alters several downstream pathways in neu-
rons (Tomlinson and Gardiner, 2008) and therefore it is conceiv-
able that themild elevation inROS is not responsible for hypergly-
cemia’s detrimental effects on nAChR function. To test whether
ROS is involved, we treated neurons with the antioxidants
a-lipoic acid (100 mM) and catalase (1000 units/ml). Neither
a-lipoic acid nor catalase individually or together had any effect
on the ACh-evoked currents in the control 5 mM glucose condi-
tion (data not shown). In contrast, a-lipoic acid and catalase pre-
vented rundown of the ACh-evoked currents on neurons in high
glucose conditions (Figures 2C and 2D). These results suggest
that hyperglycemia acts through ROS to induce rundown of the
ACh-evoked currents. This hyperglycemia-induced inactivation
of nAChRs on SCG neurons likely accounts for the depression
in synaptic transmission in SCG of diabetic mice.
Hyperglycemia-induced increase in intracellular ROS can lead
to an accumulation of the highly reactive dicarbonyl, methyl-
glyoxal (Yao et al., 2007; de Arriba et al., 2007). To test whether
methylglyoxal had a role in the use-dependent inactivation of
nAChRs, we treated neurons in high glucose cultures with the
carbonyl scavenger, aminoguanidine (Hammes et al., 1991;
Webster et al., 2005), when we elevated glucose from 5 mM
to 25 mM. We found that aminoguanidine (100–250 mM for
1–3 days) did not prevent the hyperglycemia-induced rundown
of the ACh-evoked currents (Figure 2D). These results suggest
that high glucose does not exert its effect through highly reactive
dicarbonyls.
In STZ-treated diabetic mice, circulating insulin levels are
extremely low, whereas in mice with a disruption in leptin
signaling insulin levels are high; however, synaptic transmission
in SCG is depressed in both models. This indicates that the
defect in synaptic transmission does not correlate with the circu-
lating levels of insulin. Nonetheless, we investigated whether
insulin might prevent the rundown of the ACh-evoked currents
on cultured SCG neurons in hyperglycemic conditions. Our
results indicate that adding insulin (0.530 nM) exogenously to
cultured SCG neurons was unable to stabilize the ACh-evoked
currents (Figure 2D).
ROS Attack Cys Residues in the M1-M2 Linker
to Inactivate nAChRs
Next, we investigated the molecular mechanism that underlies
the inactivation of nAChRs by hyperglycemia. From the amino830 Neuron 66, 827–834, June 24, 2010 ª2010 Elsevier Inc.acid sequence of a3 we noticed a highly conserved Cys residue,
at position 239, located near the inner mouth of the receptor
channel (Figure 3A). Since ROS is known to oxidize Cys residues,
we asked whether hyperglycemia-induced ROS inactivates
nAChRs by interacting with these Cys residues. Therefore, we
mutated the Cys at position 239 in the a3 subunit to an Ala
(a3C239A) and expressed it in cultured sympathetic neurons
from a3 null (a3 KO) mice in hyperglycemic conditions.
Sympathetic neurons from a3 KO mice do not have ACh-
evoked currents (Rassadi et al., 2005); however, expressing
either the WT or a3C239A cDNA with adenoviral vectors rescued
the ACh-evoked inward currents (Figure 3B), indicating that these
a3 subunits can coassemble with endogenous b (and possibly
other) subunits to form functional nAChRs. Equally relevant, we
showedwith repeated longpulsesofAChthat theC239Amutation
in a3 does not interfere with receptor desensitization or the
recovery fromdesensitization (Figure 3B). (Amore complete char-
acterization of the a3C239A-containing nAChRs will be described
elsewhere [A.K. and E.C., unpublished data]).
When a3 KO neurons were infected with vectors expressing
the a3WT and exposed to 25 mM glucose, the ACh-evoked
currents ran down with repeated ACh application (Figures 3C
and 3D), similar to those on WT neurons. Interestingly, however,
when a3 KO neurons were infected with vectors expressing the
a3C239A and exposed to 25 mM glucose, the ACh-evoked
currents were stable (Figures 3C and 3D). These results indicate
that inactivation of the receptor by hyperglycemia-induced ROS
involves the Cys at position 239.
Are the Cys Residues in M1-M2 Responsible for the
Depressed Synaptic Transmission in Diabetic Mice?
To test whether the C239A mutation in a3 prevents synapses in
sympathetic ganglia from hyperglycemia-induced long-lasting
depression, we infected a3 KO mice with adenoviral vectors ex-
pressing either a3WT (Ada3/Syn), a3C239A (Ada3C239A/Syn), or
control GFP (AdGFP/Syn), and 1 day later we either injected
them with STZ or control citrate buffer. a3 KO mice have no
synaptic transmission in the SCG; however, when we infected
themwith a3WT or a3C239A, we rescued the nerve-evoked EPSPs
(see also Krishnaswamy and Cooper, 2009). The nerve-evoked
EPSPs in SCG of mice infected with a3C239A were comparable
to those infected with a3WT or those in control WT mice (Fig-
ure 4A). In a3 KO mice infected with a3WT and made diabetic
with STZ, the nerve-evoked EPSPs in SCG were considerably
reduced 2 weeks after the onset of diabetes (Figures 4B and
4C), similar to the nerve-evoked EPSPs on sympathetic neurons
in SCG of diabetic WT mice. In contrast, in a3 KO mice infected
with a3C239A and made diabetic with STZ, the nerve-evoked
EPSPs in the SCG were not significantly different from those in
nondiabetic WTmice (Figures 4B and 4C). These results indicate
thatCys residues in theM1-M2 linker are responsible for the long-
lasting synaptic depression in autonomic ganglia of diabetic
mice.
Cys Residues in the M1-M2 Linker of nAChRs Underlie
Reduced Sympathetic Reflexes in Diabetic Mice
If the reduced sympathetic reflexes in diabetic mice resulted
from a depression in synaptic transmission in sympathetic
Figure 3. Hyperglycemia-Induced Elevation in ROS Inactivates
nAChRs by Interacting with Cysteine Residues Located Near the
Intracellular Mouth of the nAChR Channel
(A) Sequence alignment of several mammalian and chick nAChR subunits at
the intracellular region between the first (M1) and second (M2) transmembrane
domains. (B) ACh-evoked currents in response to three consecutive applica-
tions of ACh (100 uM, 10 s) at 1 min intervals on P2 a3 KO SCG neurons
cultured for 1 week and infected with adenoviruses containing full-length a3
(Ada3WT, top row) or with mutated a3C239A (Ada3C-A, bottom row). a3WT-
containing and a3C239A-containing nAChRs desensitize and recover similarly.
(C) Currents evoked by a series of ACh (100 mM, 1 s) applications delivered at
15 s intervals on neonatal a3 KO mouse SCG neurons cultured in 5 mM
glucose for 2 weeks, infected with either Ada3WT (top) or Ada3C239A (bottom)
and culture in 25mMglucose for 1 week. Every fourth trace is shown for clarity.
(D) Ratio of the 30th ACh-evoked current to the first in the series (I30/I1) for a3
KO neurons cultured in 5 mM glucose for 2 weeks followed by 25 mM glucose
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have normal sympathetic reflexes. To test this, we infected dia-
betic a3 KO mice with either a3WT or a3C239A and measured the
tonic sympathetic drive to the heart and thermoregulation as
above. In diabetic a3 KO mice infected with a3WT, the sympa-
thetic drive to the heart was reduced similar to that inWTdiabetic
mice. On the other hand, in diabetic a3 KO mice infected with
a3C239A, the sympathetic drive to the heart was not reduced
and was not significantly different from that in nondiabetic WT
mice (Figure 4D). Furthermore, when placed at 4C, the core
body temperature of diabetic a3 KO mice infected with a3WT
dropped by several degrees within 2 hr, similar to diabetic WT
mice, whereas when diabetic a3 KO mice infected with
a3C239A were placed at 4C their core body temperature
remained constant for at least 2–3 hr, similar to that for nondia-
betic WT mice (Figure 4E).
DISCUSSION
Our work provides a model for the cause of diabetic-induced
dysautonomias. We show that an early step leading to dysauto-
nomias in diabetes is a depression of ganglionic synaptic trans-
mission triggered by events downstream of hyperglycemia.
Our results demonstrate that diabetes induces a depression in
synaptic transmission in autonomic ganglia by elevating ROS
and inactivating a3-containing postsynaptic nAChRs. This syn-
aptic depression is apparent as early as 1 week after the onset
of diabetes and becomes more severe over time. Because these
nicotinic synapses in autonomic ganglia form a vital link between
the integrative activities of the CNS and peripheral autonomic
effector mechanisms, it is likely that most dysautonomias in dia-
betics are caused by this disruption of ganglionic transmission.
Hyperglycemia is known to elevate ROS in peripheral neurons,
although the source of this hyperglycemia-induced ROS is not
fully understood (Tomlinson and Gardiner, 2008). Our results
show that if we treat cultured sympathetic neurons with antioxi-
dants, we can prevent the hyperglycemia-induced rundown of
ACh-evoked currents. This suggests that the hyperglycemia-
induced increase in cytosolic ROS mediates the rundown of
the ACh-evoked currents on cultured sympathetic neurons by
inactivating nAChRs.
One of the consequences of increased intracellular ROS in
diabetes is accumulation of the highly reactive dicarbonyl, meth-
ylglyoxal. We find, however, that treating cultures with the
carbonyl scavenger aminoguanidine did not prevent the hyper-
glycemia-induced rundown of the ACh-evoked currents. These
results suggest that high glucose does not exert its effect on
nAChRs through highly reactive dicarbonyls.
We have not determined how ROS inactivates the receptors,
but our experiments expressing mutant a3C239A in a3 KO
neurons demonstrate that the conserved Cys residue located
near the cytoplasmic mouth of the channel is essential for the
use-dependent inactivation by hyperglycemia-induced ROS.
It is likely that these conserved Cys residues form a ring nearfor 1 week infected with either Ada3C239A (n = 25 neurons) or Ada3WT (n = 23).
Each bar is the mean I30/I1 ± SEM. ***p < 0.001.
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Figure 4. Synaptic Transmission and Sympathetic Reflexes Are
Normal in Hyperglycemic Mice Expressing a3C239A Receptors
(A) Nerve-evoked EPSPs recorded intracellularly from SCG neurons in intact
ganglia from P14 a3 KO mice (left) and P14 a3 KO mice infected at P0 with
adenoviruses that contain a3C239A. (B) EPSPs from SCG neurons in P18 a3
KO mice rescued with Ada3WT (left column) or with Ada3C239A (right column)
2 weeks after injection with control citrate buffer (top) or STZ (bottom). Mice
were diabetic within 2–3 days of STZ. (C) Integrated EPSPs from sympathetic
neurons in a3 KO mice rescued with either Ada3WT or with Ada3C239A, 1 week
(Ada3WT n = 20 neurons, Ada3C239-A n = 20) or 2 weeks (Ada3WT n = 10,
Ada3C239A n = 18) after becoming diabetic. Each bar is the mean EPSP area
as percentage of EPSPs in age-matched controls ± SEM. (D) Sympathetic
drive to the heart in diabetic a3 KO mice rescued with either Ada3WT (n = 6
mice) or with Ada3C239A (n = 7). Hyperglycemic WT mice (n = 15) and
control-injected mice are shown for comparison (n = 12). Each bar is the
mean bpm ± SEM. (E) Core body temperature measured after 2 hr at 4;C
from control mice (Control; n = 4 mice), diabetic a3 KO mice rescued with
either Ada3WT (n = 4), or with Ada3C239A (n = 5) for 2 weeks. Each bar is the
mean ± SEM. ***p < 0.001 in (C)–(E).
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Hyperglycemia Inactivates Neuronal nAChRsthe inner mouth of the receptor’s pore. Our results suggest that
a disruption of this Cys ring prevents the receptor from entering
the inactivated state. Consistent with this idea, muscle nAChRs832 Neuron 66, 827–834, June 24, 2010 ª2010 Elsevier Inc.do not have this Cys ring and are not inactivated by elevated
ROS (Campanucci et al., 2008).
Whether this Cys ring has other roles in receptor function is not
clear. It does not appear to be important for surface expression
of a3-containing nAChRs. Nor does it have an obvious role in
receptor desensitization or recovery from desensitization. One
possibility is that theseCys act to protect neurons from overstim-
ulation when the neuron is under oxidative stress, perhaps
during some pathological event, or when the neurons are tran-
siently deprived of growth factors (Campanucci et al., 2008).
Interestingly, this residue is conserved in a4 and b2 nAChR
subunits, two subunits widely expressed in the CNS, suggesting
that nAChRs expressed on central neurons would be similarly
inactivated by mild elevations in ROS.
In the STZ-treated diabetic mouse model, insulin is also
extremely low; this raises the possibility that the depression
of synaptic transmission results from low insulin as well as, or
instead of, high glucose. We think this unlikely because treat-
ing cultures with insulin and high glucose did not prevent the
rundown of ACh-evoked currents. Furthermore, ob/ob and
db/db mice are both hyperglycemic and hyperinsulinemic at
the ages used for our experiments (Chen et al., 1996; Zhang
et al., 1994), yet synaptic transmission in the SCG of these
mice was also significantly depressed. Since the common
symptom among ob/ob, db/db, and STZ-treated mice is hyper-
glycemia, these results, taken together, add good evidence
that it is hyperglycemia, and not low insulin, that depresses
synaptic transmission in sympathetic ganglia of STZ-treated
diabetic mice.
Furthermore, we show that most, if not all, of the depression
in synaptic transmission in SCG of diabetic mice is due to inac-
tivation of postsynaptic a3-containing nAChRs because we
could prevent the depression by expressing a3C239A-containing
nAChRs in diabetic a3 KO mice. In addition, we demonstrate
with two separate examples, tonic sympathetic drive of the
heart and thermoregulation, that sympathetic nerve-dependent
reflexes are reduced when ganglionic transmission is depressed
in diabeticmice, but normal in diabetic a3C239A-expressingmice.
These results provide a direct correlation between the inactiva-
tion of postsynaptic nAChRs and reduced sympathetic nerve
function. a3-containing nAChRs are also present on mammalian
parasympathetic neurons (Poth et al., 1997; Xu et al., 1999).
We did not examine the parasympathetic nervous system, but
if hyperglycemia elevates ROS in parasympathetic neurons as
it does in sympathetic neurons, we would expect that synaptic
transmission in parasympathetic ganglia would be similarly
depressed in diabetic animals.
Our results demonstrate that hyperglycemia also interferes
with the function of a3-containing nAChRs through Cys residues
on the a3 subunit. Since these Cys residues are conserved in
human a3, b4, and b2, we think it reasonable that human gangli-
onic a3-containing nAChRs would be similarly inactivated by
hyperglycemia-induced ROS. If this is the case, then it would
suggest that some dysautonomias in people with diabetes
may result from a disruption in ganglionic transmission and
produce symptoms similar to dysautonomias in people with
autoimmune autonomic ganglionopathies (Vernino et al., 2008,
2009).
Neuron
Hyperglycemia Inactivates Neuronal nAChRsEXPERIMENTAL PROCEDURES
Animals
For most experiments, we used either outcrossed C57BL/6/J - CD+ mice or
heterozygote and homozygote Ob (B6.V-Lepob/J) and Db (BKS.Cg-Dock7m
+/+ Leprdb/J) mice (Jackson Laboratory, Bar Harbor, ME). For gene transfer
experiments, we used outbred a3 KO mice, as described previously (Krish-
naswamy and Cooper, 2009). Most experiments were done with neonatal
pups (P2–P21) and young adult (1–3 month) mice, except for those with Ob
and Db mice who were 4–6 months old. For STZ injections, we withheld
food from pups (P4–P7) for 2 hr, injected them with streptozotocin (STZ,
40–60 mg/kg); for older mice, we withheld food for 6 hr before STZ injection.
One to two days after STZ injection, 80% of mice had blood glucose
>22mM (diabetic) that remained elevated. In some experiments, we implanted
an insulin pellet under the skin (2 U/24 hr/implant, LinShin, Toronto) and in-
jected them the next day with STZ (40–60 mg/kg).
Primary Cultures
Superior cervical ganglion (SCG) neurons were cultured from P1 to P3mice (as
previously described [McFarlane and Cooper, 1992; Campanucci et al., 2008])
in media containing 5 mM glucose. To eliminate nonneuronal cells, cultures
were treated with cytosine arabinoside (10 mM; Sigma, St. Louis, MO) from
day 2 to 4. For high glucose experiments, 1-week-old cultures were switched
to media containing 25 mM glucose for 1 week before measuring ACh-evoked
currents. To rule out a direct effect of STZ on ACh-evoked currents, either
neurons were cultured in 1 mM STZ for 1 week, or STZ (1 mM) was applied
acutely to neurons while recording ACh-evoked currents; STZ had no direct
effect on nAChRs. In addition, we cultured neurons in 0.5–30 nM insulin
together with 25 mM glucose for 1 week; insulin did not prevent rundown of
ACh-evoked currents.
Whole-Cell Recording
ACh-evoked currents were measured with whole-cell patch-clamp techniques
as described previously (Campanucci et al., 2008). Briefly, membrane currents
were recorded with a VE-2 amplifier (Alembic Instruments, Montreal, Quebec,
Canada) at room temperature, and the series resistancewas reduced by 80%–
98%; the currents were filtered and analyzed offline with Igor (WaveMetrics,
Lake Oswego, OR) software. Recording electrodes were filled with a solution
containing (in mM) 65 KF, 55 KAc, 5 NaCl, 0.2 CaCl2, 1 MgCl2, 10 EGTA,
2 MgATP, and 10 HEPES, and pH was adjusted to 7.2 with KOH. In some
experiments, the a-lipoic acid (100 mM; pretreated with 1000 U/ml catalase
for 1 hr at 37C) was dissolved in intracellular solution. The cultures were
perfused continuously at 1 ml/min with a solution containing (in mM)
140 NaCl, 5.4 KCl, 0.33 NaH2PO4, 0.44 KH2PO4, 2.8 CaCl2, 0.18 MgCl2,
10 HEPES, 5.6 glucose, 2 glutamine, and atropine (1 mM; Sigma). ACh (100 mM)
was dissolved in the perfusion solution and applied to neurons by pressure
ejection.
ROS Levels and Oxidative Stress
To measure protein adducts of 4-hydroxyl-2-nonenal (HNE), we fixed and per-
meabilized neurons with methanol (100%) at 20C for 10 min, added rabbit
anti 4-HNE (Alpha Diagnostics International; 1/500) and mouse anti-tyrosine
hydroxylase (Chemicon; 1/400) overnight at 4C, and then anti-rabbit Alexa
488 (Invitrogen; 1/1000) and anti-mouse rhodamine (Invitrogen; 1/400). Images
were acquired with a Zeiss LSM 510 confocal microscope and analyzed with
MetaMorph software (Universal Imaging, West Chester, PA).
To monitor ROS levels, we loaded neurons with the redox-sensitive dye
CM-H2DCFDA and acquired DIC and fluorescent images (Campanucci
et al., 2008). On the DIC images, we defined regions of interest (neuronal
cell body, excluding the nucleus) and transferred these to the fluorescent
images of the same field and quantified mean fluorescent intensity (minus
background) in 256 arbitrary units.
Recording from Sympathetic Neurons in Intact Ganglia
We recorded nerve-evoked EPSPs in SCGs with intracellular electrodes
(Krishnaswamy and Cooper, 2009). Briefly, SCG were dissected rapidly from
mice, pinned down in a recording chamber (1.5ml volume), mounted on a fixedstage of a dissectingmicroscope, and the chamberwas perfused continuously
at 3–4 ml/min with a modified oxygenated Tyrode’s (5 mM Ca2+) solution at
36C–37C. The cervical sympathetic trunk was connected to a stimulator
with a suction electrode and stimulated with brief voltage pulses. To quantify
synaptic transmission, we stimulated the preganglionic nerve at 0.5–1 Hz for
1 min and integrated individual EPSPs. For suprathreshold EPSPs, we inte-
grated the area bound by the spike and then subtracted it from the total
area; the area under the AP usually accounted for <2% of the total area.
Only neurons with membrane potentials greater than –45 mV were included
in this study.
Heart Rate and Temperature Measurements
We used a MouseOX (STARR Life Science Corp, Oakmont, PA) heart monitor
system to measure heart rate, and in some experiments, we also measured
heart rates with a three-lead electrocardiogram. Tomeasure thermoregulation,
we placed mice in a cold room at 4C and measured their body temperature
using a small (2 mm diameter) flexible rectal thermometer. Temperature-
loss experiments were stopped at 3.5 hr.
Adenoviruses
Neonatal (P0–P21) and young adult (P28–P42) a3 KO mice were infected with
Ada3/Syn or Ada3C239A/Syn adenovirus, as described previously (Krishnasw-
amy and Cooper, 2009).
Statistics
For differences in the mean fluorescent intensities, heart rates, and core
temperature measurements, we used the Student’s t test; for comparisons
of the I30/I1 ratios or EPSP areas, we used the nonparametric Mann-Whitney
test.
All procedures for animal handling were performed according to the guide-
lines of the Canadian Council on Animal Care.
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